Researchers manipulate stem cells to grow virtually any cell type or organ in the laboratory. Ultimately, these cells could repair diseased and dysfunctional organs, phasing out organ transplants. While stem cell therapies have entered the clinic, several of them have been unsuccessful because they failed to repair diseased tissue or the recipient’s body rejected the cells. In this webinar, Michael Rudnicki and Evan Snyder will discuss the factors that determine stem cell therapy success.
Topics to be covered
• Mobilizing muscle stem cells for therapy
• How a novel class of signal-modifying drugs guide stem cells to their target location
Michael Rudnicki, PhD
Senior Scientist and Director, Regenerative Medicine Program, Ottawa Hospital Research Institute
Michael Rudnicki is a senior scientist and the director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute. He is also a professor in the Department of Medicine at the University of Ottawa. Rudnicki is the CEO and scientific director of the Canadian Stem Cell Network (SCN), a national community that brought stem cell research to the point where regenerative medicine is impacting clinical practice. Rudnicki’s research is focused on understanding muscle development and regeneration, and the development of novel stem cell-based approaches to treat muscular dystrophy. Rudnicki is an officer of the Order of Canada, a fellow of the Royal Society (London), a fellow of the Royal Society of Canada, and an international research scholar of the Howard Hughes Medical Institute for two consecutive terms.
Evan Y. Snyder, MD, PhD
Professor, Human Genetics Program, Director, Center for Stem Cells and Regenerative Medicine, Sanford Burnham Prebys Medical Discovery Institute
Evan Snyder earned his MD and PhD at the University of Pennsylvania and studied psychology, philosophy, and linguistics at the University of Oxford. He completed residencies in pediatrics and neurology and a clinical fellowship in neonatal-perinatal medicine at Children's Hospital-Boston, Harvard Medical School, where he also served as chief resident in medicine and neurology and a postdoctoral research fellow in the Department of Genetics. In 1990, he received the CNS Young Investigator Award. In 1992, he joined the clinical faculty in both neonatology and neurology at Harvard Medical School, becoming the country’s first to be dual boarded in those specialties. Synder’s research defines the basic and translational properties of neural stem cells. In 2003, Snyder joined the Sanford Burnham Prebys Institute and University of California San Deigo in La Jolla, to establish a Center for Stem Cells and Regenerative Medicine. He has been elected to the Association of American Physicians and to the American Institute of Medical & Biological Engineering. He presently chairs the SAB of NIH’s Genetic Disease Biobank and is a diplomate of the Health Leadership Academy.